Postoperative transfusion hemoglobin threshold and functional recovery after high-risk oncologic surgery: A randomized controlled pilot study
- PMID: 37102357
- DOI: 10.1111/trf.17367
Postoperative transfusion hemoglobin threshold and functional recovery after high-risk oncologic surgery: A randomized controlled pilot study
Abstract
Background: Robust evidence to inform best transfusion management after major oncologic surgery, where postoperative recovery might impact treatment regimens for cancer, is lacking. We conducted a study to validate the feasibility of a larger trial comparing liberal versus restrictive red blood cells (RBC) transfusion strategies after major oncologic surgery.
Study design and methods: This was a two-center, randomized, controlled, study of patients admitted to the intensive care unit after major oncologic surgery. Patients whose hemoglobin level dropped below 9.5 g/dL, were randomly assigned to immediately receive a 1-unit RBC transfusion (liberal) or delayed until the hemoglobin level dropped below 7.5 g/dL (restrictive). The primary outcome was the median hemoglobin level between randomization to day 30 post-surgery. Disability-free survival was evaluated by the WHODAS 2.0 questionnaire.
Results: 30 patients were randomized (15 patients/group) in 15 months with a mean recruitment rate of 1.8 patients per month. The median hemoglobin level was significantly higher in the liberal group than in the restrictive group: 10.1 g/dL (IQR 9.6-10.5) versus 8.8 g/dL (IQR 8.3-9.4), p < .001, and RBC transfusion rates were 100% versus 66.7%, p = .04. The disability-free survival was similar between groups: 26.7% versus 20%, p = 1.
Discussion: Our results support the feasibility of a phase 3 randomized controlled trial comparing the impact of liberal versus restrictive transfusion strategies on the functional recovery of critically ill patients following major oncologic surgery.
Keywords: critically ill patients; functional recovery; hemoglobin threshold; oncologic surgery; pilot study; red blood cells transfusion.
© 2023 The Authors. Transfusion published by Wiley Periodicals LLC on behalf of AABB.
References
REFERENCES
-
- Ludwig H, Van Belle S, Barrett-Lee P, Birgegård G, Bokemeyer C, Gascón P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40(15):2293-306.
-
- Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med. 2004;5(116 Suppl 7A):11S-26S.
-
- van de Pol SMG, Doornaert PAH, de Bree R, Leemans CR, Slotman BJ, Langendijk JA. The significance of anemia in squamous cell head and neck cancer treated with surgery and postoperative radiotherapy. Oral Oncol. 2006;42(2):131-8.
-
- Adams A, Scheckel B, Habsaoui A, Haque M, Kuhr K, Monsef I, et al. Intravenous iron versus oral iron versus no iron with or without erythropoiesis- stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2022. Cochrane Haematology Group, Editor Cochrane Database of Systematic Reviews [Internet] 2022 Jun 20 [cited 2022 Dec 12];2022(6). Available from. 2022 CD012633. https://doi.org/10.1002/14651858.CD012633.pub2
-
- Ecker BL, Simmons KD, Zaheer S, Poe SLC, Bartlett EK, Drebin JA, et al. Blood transfusion in major abdominal surgery for malignant tumors: a trend analysis using the National Surgical Quality Improvement Program. JAMA Surg. 2016;151(6):518-25.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
